Eksenatid
Eksenatid (INN, Byetta, Bydureon) agonist je glukagonu sličnog peptida-1 (GLP-1 agonist). On pripada grupi mimetika inkretina. Ovaj lek je odobren aprila 2005. za lečenje dijabetes melitusa tipa 2.[1][2][3]
| |
| Klinički podaci | |
|---|---|
| Robne marke | Byetta, Byetta (Amylin/Eli Lilly) |
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 141758-74-9 |
| ATC kod | A10BX04 |
| DrugBank | DB01276 |
| Hemijski podaci | |
| Formula | C184H282N50O60S |
| Mol. masa | 4186.6 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 2,4 h |
| Izlučivanje | Renalno |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Reference uredi
- ↑ Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. PMID 16230722
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura uredi
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
